An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss while a ...
Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on ...
Zacks Investment Research on MSN
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know
Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a ...
Amgen's obesity drug MariTide shows promise in maintaining weight loss with less frequent dosing. In trials, it achieved up ...
Thousand Oaks-based Amgen Inc. on Jan. 6 announced it has acquired Oxford, U.K.-based Dark Blue Therapeutics Ltd., a ...
Amgen's experimental obesity drug MariTide shows promise in helping maintain weight loss, ahead of results from a mid-stage ...
If you are wondering whether Amgen's current share price still offers value after a strong run, this article walks through ...
Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...
Amgen is getting down with Disco Pharmaceuticals, commissioning the German outfit to work on cancer therapies focused on a ...
Amgen Inc. has acquired cancer drug developer Dark Blue Therapeutics Ltd. in a deal worth as much as $840 million, expanding its portfolio of oncology treatments.
The acquisition is centered on Dark Blue Therapeutics' small-molecule degrader of the MLLT1 and MLLT3 proteins, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback